Safety and Efficacy Study of Tislelizumab in Combination With BCG in HR-NMIBC Patients (TACBIN-01)

NCT04922047 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

6

Enrollment

OTHER

Sponsor class

Conditions

Urinary Bladder Neoplasms
Urologic Neoplasms
Urogenital Neoplasms
Antineoplastic Agents
Urinary Bladder Diseases
Tislelizumab Antineoplastic Agents, Immunological

Interventions

DRUG: tislelizumab and BCG

Sponsor

RenJi Hospital

Collaborators

[object Object]
[object Object]